Coronary Artery Disease Pipeline Insight

DelveInsight’s, “Coronary Artery Disease Pipeline Insight, 2022” report provides comprehensive insights about 30+ Coronary Artery Disease companies and 30+ pipeline drugs in Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. Coronary Artery Disease pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Coronary Artery Disease Understanding

Coronary Artery Disease: Overview

Coronary artery disease (CAD) is the most common type of heart disease in the United States. It is sometimes called coronary heart disease or ischemic heart disease. Coronary Artery Disease is caused by plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body.Plaque is made up of deposits of cholesterol and other substances in the artery. Plaque buildup causes the inside of the arteries to narrow over time, which can partially or totally block the blood flow. This process is called atherosclerosis. Angina, or chest pain and discomfort, is the most common symptom of CAD. Angina can happen when too much plaque builds up inside arteries, causing them to narrow. Narrowed arteries can cause chest pain because they can block blood flow to the heart muscle and the rest of the body. Overweight, physical inactivity, unhealthy eating, and smoking tobacco are risk factors for CAD. Coronary Artery Disease is one of the most common chronic conditions: Nearly 10% of people between the ages of 40 and 80 are affected by it – men more often than women. Coronary Artery Disease is a chronic disease. Someone may first notice that they have it after experiencing angina symptoms, but Coronary Artery Disease can also cause a heart attack without any previous symptoms. Sometimes a heart attack might even go unnoticed. This is known as a silent heart attack. People who have nerve damage due to diabetes, for example, might not feel the typical symptoms of a heart attack. CAD can also lead to other health problems, most commonly heart attacks, heart rhythm problems like atrial fibrillation, and heart failure (cardiac insufficiency).Some people who have Coronary Artery Disease develop depression too. This is more likely following a heart attack. The main way to diagnose CAD is with an electrocardiogram (ECG). It is also possible to do an ultrasound scan of the heart (echocardiography) or use another imaging technique to examine the heart. The person’s age, other medical conditions, and the type of symptoms will determine what additional testing might be needed. The main goals of treatment for Coronary Artery Disease are to relieve symptoms and prevent complications. Medication can reduce the symptoms and restrictions in everyday life caused by stable angina. Beta blockers, calcium channel blockers and nitrates are used for this purpose.

 

"Coronary Artery Disease Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Coronary Artery Disease pipeline landscape is provided which includes the disease overview and Coronary Artery Disease treatment guidelines. The assessment part of the report embraces, in depth Coronary Artery Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Coronary Artery Disease Pipeline Report Highlights

The Coronary Artery Disease companies and academics are working to assess challenges and seek opportunities that could influence Coronary Artery Disease R&D. The therapies under development are focused on novel approaches to treat/improve Coronary Artery Disease.

Coronary Artery Disease Emerging Drugs Chapters

This segment of the Coronary Artery Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Drugs

Company

Phase 

MoA

RoA

Evolocumab

Amgen

Phase III

PCSK9 protein inhibitor

Subcutaneous

Revacept

AdvanceCor

Phase II

Platelet membrane glycoprotein VI inhibitors

Intravenous

Atuliflapon

AstraZeneca

Phase II

5-lipoxygenase activating protein inhibitors

Oral

Selatogrel

Idorsia Pharmaceuticals

Phase II

Purinoceptor P2Y12 antagonists

Subcutaneous

AdVEGFXC1

XyloCor Therapeutics

Preclinical

Gene transference; Vascular endothelial growth factor replacements

NA

 

Coronary Artery Disease Emerging Drugs

 

Selatogrel:  Idorsia Pharmaceuticals

Selatogrel, is a small molecule being developed by Idorsia Pharmaceuticals. It acts as a P2Y12 receptor antagonist. Currently, the drug is being studied in Phase II stage of Clinical trial evaluation for the treatment of Coronary artery disease.

 

Atuliflapon: AstraZeneca

Atuliflapon (formerly AZD 5718) is an orally available, small molecule, 5-lipoxygenase activating protein inhibitor, being developed by AstraZeneca. Currently, the drug is being studied in Phase II stage of clinical trial evaluation for the treatment of Coronary artery disease.

 

XTR 003: Sinotau Pharmaceuticals

XTR003 is a PET imaging radiopharmaceutical agent used to trace myocardial fatty acid metabolism. XTR003 is a modified fatty acid that enters the myocytes and passes through mitochondrial membrane by the same process as the natural existing fatty acids and then undergoes partial β-oxidation before being trapped in the mitochondria. In preclinical study XTR003 showed high myocardial uptake and retention. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Coronary Artery Disease.

Further product details are provided in the report……..

Coronary Artery Disease Therapeutic Assessment

This segment of the report provides insights about the different Coronary Artery Disease drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Coronary Artery Disease Pipeline

There are approx. 30+ key Coronary Artery Disease companies which are developing the therapies for Coronary Artery Disease. The companies which have their Coronary Artery Disease drug candidates in the most advanced stage, i.e. Phase II include, Idorsia Pharmaceuticals.

 

Phases of Coronary Artery Disease Drugs

DelveInsight’s report covers around 30+ Coronary Artery Disease products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Coronary Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Coronary Artery Disease products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Coronary Artery Disease Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Product Type

Coronary Artery Disease drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Coronary Artery Disease Pipeline Development Activities

The Coronary Artery Disease pipeline report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Coronary Artery Disease therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The Coronary Artery Disease pipeline report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronary Artery Disease drugs.

Coronary Artery Disease Report Insights

  • Coronary Artery Disease Pipeline Analysis
  • Coronary Artery Disease Therapeutic Assessment
  • Unmet Needs
  • Impact of Coronary Artery Disease Drugs

Coronary Artery Disease Report Assessment

  • Pipeline Product Profiles
  • Coronary Artery Disease Therapeutic Assessment
  • Coronary Artery Disease Pipeline Assessment
  • Inactive Coronary Artery Disease drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Coronary Artery Disease Therapies:

  • How many Coronary Artery Disease companies are developing Coronary Artery Disease drugs?
  • How many Coronary Artery Disease drugs are developed by each company?
  • How many emerging Coronary Artery Disease drugs are in mid-stage, and late-stage of development for the treatment of Coronary Artery Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Coronary Artery Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing Coronary Artery Disease therapies?
  • What are the clinical studies going on for Coronary Artery Disease and their status?
  • What are the key designations that have been granted to the emerging Coronary Artery Disease drugs?

Frequently Asked Questions

What is Coronary Artery Disease?
Coronary artery disease (CAD) is the most common type of heart disease in the United States. It is also known as coronary heart disease or ischemic heart disease.
Who are the leading Coronary Artery Disease companies?
Key Coronary Artery Disease companies such as Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences, and others.
Which are the emerging Coronary Artery Disease therapies?
Emerging Coronary Artery Disease pipeline therapies in various stages of development include Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, REG-101, and others.
What is the scope of the Coronary Artery Disease pipeline report?
Coronary Artery Disease pipeline report provides pipeline product profiles, therapeutic assessment, pipeline assessment, inactive drugs assessment and unmet needs.

Introduction

Executive Summary

Coronary Artery Disease: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Coronary Artery Disease Pipeline Therapeutics

  • Comparative Analysis

Coronary Artery Disease Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Coronary Artery Disease– DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Selatogrel:  Idorsia Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

XTR 003: Sinotau Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Coronary Artery Disease Products

  • Comparative Analysis

Coronary Artery Disease Key Companies

Coronary Artery Disease Key Products

Coronary Artery Disease- Unmet Needs

Coronary Artery Disease- Market Drivers and Barriers

Coronary Artery Disease- Future Perspectives and Conclusion

Coronary Artery Disease Analyst Views

Coronary Artery Disease Key Companies

Appendix

List of Table

Table 1: Total Products for Coronary Artery Disease

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type                                              

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Coronary Artery Disease

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Idorsia Pharmaceuticals
• AstraZeneca
• Sinotau Pharmaceuticals
• XyloCor Therapeutics
• AdvanceCor
• Sinotau Pharmaceuticals
• GE Healthcare
• Honya Medical Inc
• Novartis Pharmaceuticals

 

Forward to Friend

Need A Quote